Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.

ABSTRACT:

Importance

Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations.

Objective

To determine whether treatment involving novel weekly and monthly subcutaneous (SC) buprenorphine depot formulations is noninferior to a daily sublingual (SL) combination of buprenorphine hydrochloride and naloxone hydrochloride in the treatment of opioid use disorder.

Design, setting, and participants

This outpatient, double-blind, double-dummy randomized clinical trial was conducted at 35 sites in the United States from December 29, 2015, through October 19, 2016. Participants were treatment-seeking adults with moderate-to-severe opioid use disorder.

Interventions

Randomization to daily SL placebo and weekly (first 12 weeks; phase 1) and mon

SUBMITTER: Lofwall MR 

PROVIDER: S-EPMC6145749 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature